Jocelyn Solis-Moreira

Feature Writer

B.Sc. Integrative Neuroscience, M.Sc. Psychology

Jocelyn Solis-Moreira graduated with a Bachelor's in Integrative Neuroscience, where she then pursued graduate research looking at the long-term effects of adolescent binge drinking on the brain's neurochemistry in adulthood. She is adept at translating and summarizing complex study findings in all medical fields with a particular interest in neurodegenerative diseases, cancer research, infectious diseases, and public health. As a freelance writer, her work spans from news articles and feature articles to evergreen explainers across many publications. Her overall goal is to make science accessible for all.

Articles from Jocelyn

Researchers show potential benefits of delaying second mRNA COVID-19 vaccine dose

The currently approved mRNA vaccines from Moderna and Pfizer-BioNTech help create neutralizing antibodies against the SARS-CoV-2 spike protein. Both companies designed their vaccines to be delivered in two doses. However, given the limited supply of vaccines worldwide, a new modeling study has suggested that vaccinating more people with the first dose and delaying the second could be an alternate route to achieving population immunity that could reduce mortality rates.

4 Mar 2021

Multiple COVID-19 variants of concern have reached Houston, Texas

New research by a team at Houston Methodist Hospital in the United States has modeled the aggressive genomic sequencing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) observed in the United Kingdom to document viral community spread in Houston, Texas.

4 Mar 2021

Pfizer SARS-CoV-2 vaccine effective from day 11 post 1st vaccination

New research from a team of scientists in Australia finds that the second ‘booster’ dose of the Pfizer-BioNTech vaccine did not increase vaccine efficacy against severe acute respiratory syndrome (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19). The results suggest one dose of the vaccine was sufficient in providing a robust immune response 11 days after inoculation.

3 Mar 2021

Muscle strength associated with reduced COVID-19 hospitalization in older adults

Exercising more than once a week after 50 years of age is linked to a 60% lower risk of COVID-19 hospitalization. An international team of researchers has found that physical activity involving muscle training can be protective against severe infection.

3 Mar 2021

Scientists establish infection models for SARS-CoV-2 UK & South African variants

New research suggests Syrian golden hamsters could be a potentially useful preclinical model for testing vaccine immunity against the acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.17 and B.1.351 variant.

1 Mar 2021

Enduring antibody response observed after natural immunity and first Pfizer SARS-CoV-2 vaccine shot

Immunity gained after natural infection from the acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is boosted when people take the first Pfizer-BioNTech vaccine, according to a new study led by Iain C. Chapple from the University of Birmingham.

1 Mar 2021

Pfizer-BioNTech SARS-CoV-2 vaccine effective for wide range of Covid-19–related outcomes

The Pfizer-BioNTech mRNA vaccine was shown to be 95% effective in preventing severe COVID-19 infection in clinical trials. However, given that the acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread and evolve into several concerning variants, it remained unknown how the vaccine would respond in a real-life setting.

1 Mar 2021

COVID-19 CG tracks local SARS-CoV-2 mutations by geographical location

Genomic surveillance of acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has varied across countries. England's increased coronavirus sequencing helped it uncover the B.1.1.7 variant last fall. In contrast, countries such as the United States have reported little sequencing data.

28 Feb 2021

New evidence of SARS-CoV-2 spreading on planes

New research from the Centers for Disease Control and Prevention (CDC) journal Emerging Infectious Diseases analyzed a case showing in-flight transmission of acute respiratory syndrome coronavirus 2 (SARS-CoV-2) despite passengers getting tested before departing to New Zealand.

28 Feb 2021

New SARS-CoV-2 B.1.526 variant emerges in New York

New York has the first case of a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant called B.1.526, picked up by genomic surveillance research from Columbia University. The findings come after reports of other variants have been reported worldwide — B.1.1.7 in the United Kingdom, B.1.351 in South Africa, and P.1/P.2 in Brazil.

28 Feb 2021